Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing

Abstract excerpt

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified medical device, which requires premarket approval or de novo classification. Opponents of the FDA's action expressed...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Ethics and Regulation
• Share to BRCA gene mutations in cancer
• Share to Nutrition, Genetics, and Disease